Stocks · News reference
Humacyte Announces Publication Of One-Year V007 Phase 3 Results In The Lancet Digital Health Showing ATEV Superiority Over Autogenous Fistula For Hemodialysis Access
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Humacyte Reports Accelerating Commercial Adoption, Reports 44% Increase In Hospitals Ordering Symvess To 49 In Q3 2026
Humacyte Says Interim Phase 3 Data For ATEV In Dialysis Access To Be Presented October 22, sBLA Filing Expected This Quarter
Barclays Initiates Coverage On Humacyte with Equal-Weight Rating, Announces Price Target of $0.5
Barclays analyst Christopher Pasquale initiates coverage on Humacyte (NASDAQ:HUMA) with a Equal-Weight rating and announces Price Target of $0.5.